Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.65 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.65 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10534175 | 0.98 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL151361 | 0.98 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL249052 | 0.98 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL10535931 | 0.98 | L3MBTL1 (1.00) | L3MBTL1MEN1KMT2ATDP1ATM | |
| N-(Decanoyl)Pyrrolidine SCHEMBL10755236 | 0.98 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1ATM | |
| N-(Decanoyl)Pyrrolidine SCHEMBL692598 | 0.98 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL10494122 | 0.98 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL10534171 | 0.98 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL1492484 | 0.98 | L3MBTL1 (1.00) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL10290341 | 0.98 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-115385902-B | Benzimidazole compound, and preparation method and application thereof | 徐州医科大学 | 2024-03-29 | — | — | CN | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-3907237-A1 | APJ RECEPTOR AGONISTS AND USES THEREOF | Amgen Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-2629889-B1 | RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RES & DEV (IL) | 2019-04-03 | — | — | EP | disclosed |
| EP-3345917-A1 | ANTIPROTOZOAL COMPOUNDS | Bacoba AG (CH) | 2018-07-11 | — | — | EP | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9738685-B2 | Use of ruthenium complexes for preparing amides, polypeptides and cyclic dipeptides | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-08-22 | — | — | US | disclosed |
| US-9738685-B2 | Use of ruthenium complexes for preparing amides, polypeptides and cyclic dipeptides | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-08-22 | — | — | US | disclosed |
| CN-1306935-C | Vasopressin antagonist and oxytocin antagonist | OTASUKA PHARMACEUTICAL CO LTD (JP) | 2007-03-28 | — | — | CN | disclosed |
| EP-0981539-A1 | DOLASTATIN 15 DERIVATIVES WITH CARBONYL AND HETEROCYCLIC FUNCTIONALITIES AT THE C-TERMINUS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-01 | — | — | EP | disclosed |
| US-5965537-A | ANTICANCER AGENTS; WATER SOLUBILITY | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-12 | — | — | US | disclosed |
| CN-1039999-C | Vasopressin antagonist and oxytocin antagonist, process for their preparation and pharmaceutical compositions containing them | OTSUKA CHEMICAL CO LTD (JP) | 1998-09-30 | — | — | CN | disclosed |
| WO-1998040400-A1 | DOLASTATIN 15 DERIVATIVES WITH CARBONYL AND HETEROCYCLIC FUNCTIONALITIES AT THE C-TERMINUS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
| CN-1183277-A | Vasopressin antagonist and oxytocin antagonist | OTASUKA PHARMACEUTICAL CO LTD (JP) | 1998-06-03 | — | — | CN | disclosed |
| CN-1098716-A | Vasopressin antagonists and oxytocin antagonists | OTSUKA CHEMICAL CO LTD (JP) | 1995-02-15 | — | — | CN | disclosed |
| US-4837026-A | Transdermal and systemic preparation and method | THERAPEUTIC PATCH RESEARCH N.V. | 1989-06-06 | — | — | US | disclosed |
| EP-0240554-A1 | TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD | RAJADHYAKSHA, Vithal J. (US) | 1987-10-14 | — | — | EP | disclosed |
| WO-1987001935-A1 | TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD | RAJADHYAKSHA VITHAL J | 1987-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | L3MBTL1 3926/4885MEN1 2811/4885KMT2A 2535/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885MEN1 4055/4885KMT2A 445/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | L3MBTL1 2977/4885MEN1 2517/4885KMT2A 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.